54706-99-9
中文名称
20-去氧巨大戟萜醇
英文名称
20-DEOXYINGENOL
CAS
54706-99-9
分子式
C20H28O4
分子量
332.43
MOL 文件
54706-99-9.mol
更新日期
2024/04/29 17:26:59
54706-99-9 结构式
基本信息
中文别名
20-去氧巨大戟醇20-去氧巨大戟萜醇
20-脱氧-巨大戟醇
20-脱氧巨大戟萜醇
20-去氧巨大戟醇, >98%
英文别名
20-DEOXYINGENOL20-Deoxyingenol, >98%
20-deoxyingenol 54706-99-9
(1aR,10aα)-1a,2,5,5a,6,9,10,10a-Octahydro-5β,5aβ,6β-trihydroxy-1,1,4,7,9α-pentamethyl-1H-2α,8aα-methanocyclopenta[a]cyclopropa[e]cyclodecen-11-one
1H-2,8a-Methanocyclopenta[a]cyclopropa[e]cyclodecen-11-one, 1a,2,5,5a,6,9,10,10a-octahydro-5,5a,6-trihydroxy-1,1,4,7,9-pentamethyl-, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-
所属类别
生物化工：植物提取物物理化学性质
熔点208-209℃ (分解)
沸点470.5±45.0 °C(Predicted)
密度1.26±0.1 g/cm3 (20 ºC 760 Torr)
储存条件-20°C储存
溶解度DMSO : 50 mg/mL (150.41 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
酸度系数(pKa)12.21±0.70(Predicted)
形态粉末
20-去氧巨大戟萜醇价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-N0866 | 20-去氧巨大戟萜醇 20-Deoxyingenol | 54706-99-9 | 5mg | 1000元 |
| 2024/04/30 | HY-N0866 | 20-去氧巨大戟萜醇 20-Deoxyingenol | 54706-99-9 | 10mM * 1mLin DMSO | 1100元 |
| 2024/01/25 | HY-N0866 | 20-去氧巨大戟萜醇 20-Deoxyingenol | 54706-99-9 | 10mg | 1800元 |
常见问题列表
生物活性
20-Deoxyingenol 是一种从 Euphorbia kansui 的根中分离出的二萜。20-Deoxyingenol 可通过促进体外转录因子 EB (TFEB) 的核易位来促进自噬和溶酶体生物发生。20-Deoxyingenol 可用于骨关节炎 (OA) 的研究。体外研究
20-Deoxyingenol (2.5-10 mM; 24 h) protects chondrocytes against Tert-butyl hydroperoxide solution (TBHP; 100 μM)-induced cell death.
20-Deoxyingenol (5-10 mM) decreases the TBHP-induced upregulation of apoptosis protein cleaved-caspase3 and the senescence protein p16INK4a in chondrocytes.
20-Deoxyingenol (2.5-40 mM; 24 h) has no cytotoxic effect on chondrocytes at the concentration less than 10 mM.
20-Deoxyingenol (10 mM; 24 h) restores autophagy flux in TBHP treated chondrocytes.
20-Deoxyingenol (4-10 mM; 24 h) promotes the nuclear level of TFEB in TBHP treated chondrocytes.
体内研究
20-Deoxyingenol (20 mg/kg/d; i.p. for 8 weeks) alleviates the progression of OA in the DMM model in mice.
| Animal Model: | 10-week-old C57BL/6 male wild-type (WT) mice with destabilization of the medial meniscus (DMM) |
| Dosage: | 20 mg/kg |
| Administration: | I.p. one time per day, for eight consecutive weeks |
| Result: |
Had a slightly wider joint space and reduced bone density and calcification compared with the DMM group.
Inhibited the decrease in the thickness of hyaline cartilage (HC), and alleviated the disorder and hypertrophy of chondrocytes in the joint tissues of mice after DMM surgery. Had less erosion on the surface of the articular cartilage and more proteoglycan content. Had more positive staining points of LAMP1 and LC3 II, and less cleaved-caspase3 and P16INK4a. Increased the nuclear level of TFEB. |